Cholesterol biogenesis is a PTEN‐dependent actionable node for the treatment of endocrine therapy‐refractory cancers
Cancer Science · 2023
DOI: 10.1111/cas.15960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Irmak Kaysudu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Endometrial Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
PTEN and PIK3CA mutations are the most prevalent PI3K pathway alterations in prostate, breast, colorectal, and endometrial cancers. p110β becomes the prominent PI3K isoform upon PTEN loss. In this study, we aimed to understand the molecular mechanisms of PI3K dependence in the absence of PTEN. Using online bioinformatical tools, we examined two publicly available microarray datasets with aberrant PI3K activation. We found that the rate‐limiting enzyme of cholesterol biogenesis, SQLE, was significantly upregulated in p110β‐hyperactivated or PTEN‐deficient mouse prostate tumors. Concomitantly, the expression of cholesterol biosynthesis pathway enzymes was directly correlated with PI3K activation status in microarray datasets and diminished upon PTEN re‐expression in PTEN‐null prostate cancer cells. Particularly, PTEN re‐expression decreased SQLE protein levels in PTEN‐deficient prostate cancer cells. We performed targeted metabolomics and detected reduced levels of cholesteryl esters as well as free cholesterol upon PTEN re‐expression. Notably, PTEN‐null prostate and breast cancer cell lines were more sensitive to pharmacological intervention with the cholesterol pathway than PTEN‐replete cancer cells. Since steroid hormones use sterols as structural precursors, we studied whether cholesterol biosynthesis may be a metabolic vulnerability that enhances antihormone therapy in PTEN‐null castration‐resistant prostate cancer cells. Coinhibition of cholesterol biosynthesis and the androgen receptor enhanced their sensitivity. Moreover, PTEN suppression in endocrine therapy‐resistant luminal‐A breast cancer cells leads to an increase in SQLE expression and a corresponding sensitization to the inhibition of cholesterol synthesis. According to our data, targeting cholesterol biosynthesis in combination with the hormone receptor signaling axis can potentially treat hormone‐resistant prostate and breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
- Institute of Environmental Sciences, Bogazici University, Istanbul, Turkey.
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
- Department of Biochemistry and Molecular Biology, Hollings Cancer Center, MUSC, Charleston, South Carolina, USA.
- Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey.
ORCID-Profile: Onur Cizmecioglu
Förderung
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Kaysudu, I., Gungul, T. B., Atici, S., Yilmaz, S., Bayram, E., Guven, G., Cizmecioglu, N. T., Sahin, O., Yesiloz, G., Haznedaroglu, B. Z., & Cizmecioglu, O. (2023). Cholesterol biogenesis is a PTEN‐dependent actionable node for the treatment of endocrine therapy‐refractory cancers. Cancer Science. https://doi.org/10.1111/cas.15960
Vancouver
Kaysudu I, Gungul TB, Atici S, Yilmaz S, Bayram E, Guven G, et al. Cholesterol biogenesis is a PTEN‐dependent actionable node for the treatment of endocrine therapy‐refractory cancers. Cancer Science. 2023. doi:10.1111/cas.15960
BibTeX
@article{Kaysudu2023,
author = {Kaysudu, Irmak and Gungul, Taha Bugra and Atici, Sena and Yilmaz, Sevval and Bayram, Engin and Guven, Gozde and Cizmecioglu, Nihal Terzi and Sahin, Ozgur and Yesiloz, Gurkan and Haznedaroglu, Berat Zeki and Cizmecioglu, Onur},
title = {Cholesterol biogenesis is a PTEN‐dependent actionable node for the treatment of endocrine therapy‐refractory cancers},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15960}
}
EUVIMED